| News
Artidis joins world’s largest medical center
19.11.2019
The Basel-based startup Artidis is developing a medical device based on nanotechnology to help with cancer diagnoses. The spin-off from the University of Basel has now been successfully integrated in the Texas Medical Center and will therefore have access to the US market.

The team of Artidis, a spin off from the University of Basel (Photo: Artidis)
In a press release, the University of Basel describes the Texas Medical Center (TMC) as the “world’s largest medical center”. Its capacities in the life sciences sector are complemented by the expertise of companies that qualify for the TMC Innovation Accelerator. This year, a total of 140 startups applied to join the international cohort of medical devices, with 16 ultimately proving successful. Artidis, a spin-off from the University of Basel, was one of the successful applicants.
Artidis, which was formed from a research group comprising the University of Basel and the Swiss Nanoscience Institute, has used its proprietary nanotechnology platform in order to develop “the first nanomechanical biomarker for cancer diagnosis and treatment optimization”. The platform integrates different types of clinical data, allowing current diagnostic processes to be shortened and personalized plans for cancer treatment to be produced. As part of the TMC, Artidis can now launch this technology on the US market. “Being part of the TMC Innovation Accelerator program is a great opportunity for us as it provides access to a unique environment at the forefront of science and innovation – the best place to take patient care to the next level”, says Marija Plodinec, CEO of Artidis, in the press release.
BaselArea.swiss has also recognized the potential of Artidis. In this regard, the startup has taken part in the location marketing organization’s Venture Mentoring program.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More